journal
https://read.qxmd.com/read/38603589/artificial-intelligence-enhanced-electrocardiogram-analysis-for-identifying-cardiac-autonomic-neuropathy-in-patients-with-diabetes
#1
JOURNAL ARTICLE
Krzysztof Irlik, Hanadi Aldosari, Mirela Hendel, Hanna Kwiendacz, Julia Piaśnik, Justyna Kulpa, Paweł Ignacy, Sylwia Boczek, Mikołaj Herba, Kamil Kegler, Frans Coenen, Janusz Gumprecht, Yalin Zheng, Gregory Y H Lip, Uazman Alam, Katarzyna Nabrdalik
AIM: To develop and employ machine learning (ML) algorithms to analyse electrocardiograms (ECGs) for the diagnosis of cardiac autonomic neuropathy (CAN). MATERIALS AND METHODS: We used motif and discord extraction techniques, alongside long short-term memory networks, to analyse 12-lead, 10-s ECG tracings to detect CAN in patients with diabetes. The performance of these methods with the support vector machine classification model was evaluated using 10-fold cross validation with the following metrics: accuracy, precision, recall, F1 score, and area under the receiver-operating characteristic curve (AUC)...
April 11, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38602411/safety-and-efficacy-of-teplizumab-in-the-treatment-of-type-1-diabetes-mellitus-an-updated-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#2
JOURNAL ARTICLE
Gabriel Grando Alves, Luisa Cunha, Rafael Henkes Machado, Vanessa Lins de Menezes
AIM: To provide updated efficacy and safety information for teplizumab in the treatment of Stage 3 type 1 diabetes mellitus (T1DM). MATERIALS AND METHODS: The PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) comparing teplizumab to placebo for T1DM that reported any of the following outcomes: (1) C-peptide area under the curve (AUC); (2) glycated haemoglobin (HbA1c) levels; (3) insulin requirements; and (4) adverse events...
April 11, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38602409/retagliptin-as-add-on-therapy-to-metformin-in-chinese-patients-with-type-2-diabetes-inadequately-controlled-with-metformin-a-multicentre-randomized-double-blind-placebo-controlled-phase-3-trial
#3
JOURNAL ARTICLE
Lixin Guo, Fengsheng Tian, Li Liu, Mingwei Chen, Chengxia Jiang, Shuangqing Li, Cong Liu, Yawei Zhang, Jie Qin, Dongni Yu, Yicen Zong, Wei Dai
AIM: To evaluate the efficacy and safety of retagliptin in Chinese patients with type 2 diabetes (T2D) inadequately controlled with metformin. MATERIALS AND METHODS: This multicentre, phase 3 trial consisted of a 16-week, randomized, double-blind, placebo-controlled period, where patients with HbA1c levels between 7.5% and 11.0% were randomized to receive either once-daily (QD) retagliptin 100 mg (n = 87) or placebo (n = 87), both as an add-on to metformin...
April 11, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38602398/the-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-inflammatory-biomarkers-a-meta-analysis-of-randomized-controlled-trials
#4
JOURNAL ARTICLE
Leonardo Buttice, Maryam Ghani, Janahan Suthakar, Sathyan Gnanalingham, Elliott Carande, Brett W C Kennedy, Alex Pitcher, James H P Gamble, Mahmood Ahmad, Andrew Lewis, Peter Jüni, Oliver J Rider, Jeffrey W Stephens, Jonathan J H Bray
AIMS: To conduct a meta-analysis of randomized controlled trials (RCTs) to assess the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on inflammatory biomarkers. METHODS: Medline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity. RESULTS: Thirty-eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8...
April 11, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38600796/real-world-treatment-satisfaction-with-dulaglutide-and-its-influencing-factors-in-a-chinese-population-with-type-2-diabetes-mellitus
#5
LETTER
Lixin Guo, Yue Xi, Li Li, Kunquan Guo, Jun Wu, Jiawei Xu, Yihua Wang, Guangyu Wu, Si Si
No abstract text is available yet for this article.
April 10, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38584567/prediction-of-new-onset-heart-failure-in-patients-with-type-2-diabetes-derived-from-altitude-and-canvas
#6
JOURNAL ARTICLE
Fatema Said, Clare Arnott, Adriaan A Voors, Hiddo J L Heerspink, Jozine M Ter Maaten
AIM: To create and validate a prediction model to identify patients with type 2 diabetes (T2D) at high risk of new-onset heart failure (HF), including those treated with a sodium-glucose cotransporter-2 (SGLT2) inhibitor. METHODS: A prediction model was developed from the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE), a trial in T2D patients with albuminuria or cardiovascular disease. We included 5081 patients with baseline N-terminal pro B-type natriuretic peptide (NT-proBNP) measurement and no history of HF...
April 8, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38584515/sleep-duration-and-association-with-cardiometabolic-health-in-adolescents-and-adults-with-type-1-diabetes-results-from-the-bcqr-t1d-study
#7
JOURNAL ARTICLE
Stacey L Simon, Janet K Snell-Bergeon, Michal Schäfer, Alex J Barker, Lorna P Browne, Uyen Truong, Shoshana S Tell, Timothy Vigers, Amy D Baumgartner, Ellen Lyon, Sarit Polsky, Irene E Schauer, Kristen J Nadeau
AIM: Type 1 diabetes (T1D) increases the risk of morbidity and mortality from cardiovascular disease, and insufficient sleep is prevalent. Emerging evidence suggests a link between sleep and cardiometabolic health, but this has not been examined across the lifespan in individuals with T1D. We aimed to examine associations between sleep and cardiometabolic health in adolescents and adults with T1D in a secondary analysis of data from a 4-week double-blind, random-order, placebo-controlled crossover trial of bromocriptine quick release (BCQR) therapy with a 4-week washout in between conditions...
April 8, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38576082/a-comment-on-glucagon-like-peptide-1-receptor-agonists-and-risk-of-thyroid-cancer-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#8
LETTER
Ronald M Goldenberg
No abstract text is available yet for this article.
April 4, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38572593/improved-glycaemic-control-induced-by-evening-activity-breaks-does-not-persist-overnight-amongst-healthy-adults-a-randomized-crossover-trial
#9
JOURNAL ARTICLE
Jennifer T Gale, Jillian J Haszard, Meredith C Peddie
AIMS: To compare the effects of 4 hours of laboratory-based regular activity breaks (RABs) and prolonged sitting (SIT) on subsequent 48-h free-living interstitial glucose levels in a group of healthy adults. MATERIALS AND METHODS: In this randomized crossover trial, participants completed two 4-h laboratory-based interventions commencing at ~5:00 pm: (1) SIT and (2) SIT interrupted with 3 min of body weight resistance exercise activity breaks every 30 min (RABs)...
April 4, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38567410/healthy-outcomes-through-peer-educators-feasibility-of-a-peer-support-diabetes-prevention-programme-for-african-american-grandmother-caregivers
#10
JOURNAL ARTICLE
Eva M Vivian, Betty A Chewning, Corrine I Voils, Roger L Brown
AIM: To assess the protocol feasibility and intervention acceptability of a community-based, peer support diabetes prevention programme (DPP) for African-American (AA) grandmother caregivers at risk for diabetes. MATERIALS AND METHODS: Grandmother caregivers were randomized in a 2:1 ratio to DPP (active comparator) or DPP plus HOPE (Healthy Outcomes through Peer Educators; intervention). DPP + HOPE incorporated support from a peer educator who met with participants in person or by telephone every week during the 1-year intervention...
April 3, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38562018/dual-glucagon-like-peptide-1-and-glucagon-receptor-agonism-reduces-energy-intake-in-type-2-diabetes-with-obesity
#11
JOURNAL ARTICLE
Rajna Golubic, Jane Kennet, Victoria Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Phil Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark Evans
AIMS: To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in early-phase studies. MATERIALS AND METHODS: We conducted a phase 2a, single-centre, randomized, placebo-controlled trial in overweight and obese adults with type 2 diabetes. Following a 16-day single-blind placebo run-in, participants were randomized 2:1 to double-blind 42-day subcutaneous treatment with cotadutide (100-300 μg daily) or placebo...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38560765/evaluating-the-global-impact-of-low-physical-activity-on-type-2-diabetes-insights-from-the-global-burden-of-disease-2019-study
#12
JOURNAL ARTICLE
Juan Luo, Xinlan Zhao, Qianru Li, Binbin Zou, Wen Xie, Yanjun Lei, Jinglin Yi, Chi Zhang
AIM: We aimed to assess the global implications of low physical activity (LPA) on type 2 diabetes mellitus (T2DM) by utilizing data from the Global Burden of Disease (GBD) 2019. METHODS: The analysis was conducted by examining the age-standardized disability-adjusted life years (DALYs) rates over a 30-year period. To assess the trends, we utilized estimated annual percentage changes (EAPCs). RESULTS: The study revealed a notable increase in the burden of DALYs attributable to T2DM resulting from LPA, with an EAPC of 0...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38560764/the-dual-gcgr-glp-1r-agonist-survodutide-biomarkers-and-pharmacological-profiling-for-clinical-candidate-selection
#13
JOURNAL ARTICLE
Leo Thomas, Eric Martel, Wolfgang Rist, Ingo Uphues, Dieter Hamprecht, Heike Neubauer, Robert Augustin
AIM: To describe the biomarker strategy that was applied to select survodutide (BI 456906), BI 456908 and BI 456897 from 19 dual glucagon receptor (GCGR)/ glucagon-like peptide-1 receptor (GLP-1R) agonists for in-depth pharmacological profiling, which led to the qualification of survodutide as the clinical development candidate. MATERIALS AND METHODS: Potencies to increase cyclic adenosine monophosphate (cAMP) were determined in Chinese hamster ovary (CHO)-K1 cells stably expressing human GCGR and GLP-1R...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38558527/differential-effect-of-endogenous-glucagon-like-peptide-1-on-prandial-glucose-counterregulatory-response-to-hypoglycaemia-in-humans-with-and-without-bariatric-surgery
#14
JOURNAL ARTICLE
Henri Honka, Amalia Gastaldelli, Samantha Pezzica, Richard Peterson, Ralph DeFronzo, Marzieh Salehi
AIM: To determine the effect of endogenous glucagon-like peptide 1 (GLP-1) on prandial counterregulatory response to hypoglycaemia after gastric bypass (GB). MATERIALS AND METHODS: Glucose fluxes, and islet-cell and gut hormone responses before and after mixed-meal ingestion, were compared during a hyperinsulinaemic-hypoglycaemic (~3.2 mmol/L) clamp with and without a GLP-1 receptor (GLP-1R) antagonist exendin-(9-39) infusion in non-diabetic patients who had previously undergone GB compared to matched participants who had previously undergone sleeve gastrectomy (SG) and non-surgical controls...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38558524/short-frequent-light-intensity-walking-activity-improves-postprandial-vascular-inflammatory-biomarkers-in-people-with-type-1-diabetes-the-sit-less-randomized-controlled-trial
#15
JOURNAL ARTICLE
Nawaz Z Safdar, Anwar M Alobaid, Mark Hopkins, Paddy C Dempsey, Sam M Pearson, Noppadol Kietsiriroje, Rachel Churm, Ramzi A Ajjan, Matthew D Campbell
AIM: To examine the effect of interrupting prolonged sitting with short, frequent, light-intensity activity on postprandial cardiovascular markers in people with type 1 diabetes (T1D). MATERIALS AND METHODS: In a randomized crossover trial, 32 adults with T1D (mean ± SD age 28 ± 5 years, glycated haemoglobin 67.9 ± 12.6 mmol/mol, 17 women) completed two 7-h laboratory visits separated by >7 days...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38558517/combined-intake-of-caffeine-and-low-dose-glucose-to-reduce-exercise-related-hypoglycaemia-in-individuals-with-type-1-diabetes-on-ultra-long-acting-insulin-degludec-a-randomized-controlled-double-blind-cross-over-trial
#16
JOURNAL ARTICLE
Tobias Kühne, Esmè Wallace, David Herzig, Simon Helleputte, Sam Scott, Jordan Pickles, Andreas Melmer, Christoph Stettler
AIM: To evaluate whether caffeine combined with a moderate amount of glucose reduces the risk for exercise-related hypoglycaemia compared with glucose alone or control in adult people with type 1 diabetes using ultra-long-acting insulin degludec. MATERIALS AND METHODS: Sixteen participants conducted three aerobic exercise sessions (maximum 75 min) in a randomized, double-blind, cross-over design. Thirty minutes before exercise, participants ingested a drink containing either 250 mg of caffeine + 10 g of glucose + aspartame (CAF), 10 g of glucose + aspartame (GLU), or aspartame alone (ASP)...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38558509/the-need-for-registry-based-studies-in-diabetes-and-stroke-a-unique-opportunity-to-understand-whether-diabetic-treatments-improve-post-stroke-outcome
#17
JOURNAL ARTICLE
Vladimer Darsalia, Ellen Vercalsteren, Dimitra Karampatsi, Mihaela Oana Romanitan, Michael V Mazya, Thomas Nyström, Cesare Patrone
No abstract text is available yet for this article.
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38558508/immunogenicity-efficacy-and-safety-of-biosimilar-insulin-glargine-gan-lee-glargine-compared-with-originator-insulin-glargine-lantus%C3%A2-in-patients-with-type-2-diabetes-after-26%C3%A2-weeks-treatment-a-randomized-open-label-study
#18
JOURNAL ARTICLE
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny Sugimoto, Joseph Soufer, Douglas Young, Mark Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
AIM: To evaluate the equivalence of immunogenicity, safety and efficacy of Gan & Lee (GL) Glargine (Basalin®; Gan & Lee Pharmaceutical) with that of the reference product (Lantus®) in adult participants with type 2 diabetes mellitus. METHODS: This was a phase 3, multicenter, open-label, equivalence trial conducted across 57 sites. In total, 567 participants with type 2 diabetes mellitus were randomized in a 1:1 ratio to undergo treatment with either GL Glargine or Lantus® for 26 weeks...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38558498/cardiovascular-health-metrics-defined-by-life-s-essential-8-scores-and-subsequent-macrovascular-and-microvascular-complications-in-individuals-with-type-2-diabetes-a-prospective-cohort-study
#19
JOURNAL ARTICLE
Ze-Gui Huang, Jing-Wei Gao, Hai-Feng Zhang, Si You, Zhuo-Chao Xiong, Yu-Biao Wu, Da-Chuan Guo, Jing-Feng Wang, Yang-Xin Chen, Shao-Ling Zhang, Pin-Ming Liu
AIM: To investigate the association between cardiovascular health metrics defined by Life's Essential 8 (LE8) scores and vascular complications among individuals with type 2 diabetes (T2D). MATERIALS AND METHODS: This prospective study included 11 033 participants with T2D, all devoid of macrovascular diseases (including cardiovascular and peripheral artery disease) and microvascular complications (e.g. diabetic retinopathy, neuropathy and nephropathy) at baseline from the UK Biobank...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38558314/impact-of-empagliflozin-on-insulin-needs-in-patients-with-heart-failure-and-diabetes-an-emperor-pooled-analysis
#20
JOURNAL ARTICLE
Khawaja M Talha, Jennifer Green, Gerasimos Filippatos, Stuart Pocock, Faiez Zannad, Martina Brueckmann, Elke Schueler, Anne Pernille Ofstad, João Pedro Ferreira, Stefan D Anker, Javed Butler, Julio Rosenstock, Milton Packer
AIM: To assess the effect of empagliflozin on patients with comorbid heart failure (HF) and diabetes with or without baseline insulin, and to study the impact of empagliflozin on insulin requirements over time. MATERIALS AND METHODS: We performed a post-hoc analysis of pooled patient-level data from two cardiovascular outcomes trials of empagliflozin in HF (EMPEROR-Reduced and EMPEROR-Preserved trials). We undertook a subgroup analysis stratified by baseline insulin use, including all patients with diabetes...
April 1, 2024: Diabetes, Obesity & Metabolism
journal
journal
34603
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.